Market closedNon-fractional
Cyclo Therapeutics/CYTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cyclo Therapeutics
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Ticker
CYTH
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Gainesville, United States
Employees
8
Website
cyclotherapeutics.com
CYTH Metrics
BasicAdvanced
$36M
Market cap
-
P/E ratio
-$0.94
EPS
-0.18
Beta
-
Dividend rate
Price and volume
Market cap
$36M
Beta
-0.18
Financial strength
Current ratio
1.005
Quick ratio
0.469
Long term debt to equity
2.87
Total debt to equity
109.024
Management effectiveness
Return on assets (TTM)
-223.69%
Return on equity (TTM)
-22,663.91%
Valuation
Price to revenue (TTM)
22.999
Price to book
57.86
Price to tangible book (TTM)
57.86
Price to free cash flow (TTM)
-1.439
Growth
Revenue change (TTM)
-15.51%
Earnings per share change (TTM)
-51.92%
3-year revenue growth
6.38%
3-year earnings per share growth
-38.05%
What the Analysts think about CYTH
Analyst Ratings
Majority rating from 3 analysts.
CYTH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
-33.33%
Net income
-$4.3M
-23.21%
Profit margin
-2,150.00%
15.18%
CYTH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q1 24
Q2 24
Actual
-$0.33
-$0.15
-
Expected
-$0.44
-$0.21
-$0.16
Surprise
-25.00%
-26.83%
-
CYTH News
AllArticlesVideos
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Business Wire·2 weeks ago
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Business Wire·1 month ago
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cyclo Therapeutics stock?
Cyclo Therapeutics (CYTH) has a market cap of $36M as of July 06, 2024.
What is the P/E ratio for Cyclo Therapeutics stock?
The price to earnings (P/E) ratio for Cyclo Therapeutics (CYTH) stock is 0 as of July 06, 2024.
Does Cyclo Therapeutics stock pay dividends?
No, Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Cyclo Therapeutics dividend payment date?
Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Cyclo Therapeutics?
Cyclo Therapeutics (CYTH) has a beta rating of -0.18. This means that it has an inverse relation to market volatility.
Buy or sell Cyclo Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.